Wugen is developing off-the-shelf allogeneic cellular therapies, including CAR-T and NK cell treatments, specifically targeting solid tumors and hematologic malignancies. These therapies aim to provide effective treatment options for patients with relapsed or refractory cancers, utilizing engineered cells derived from healthy donors to enhance therapeutic efficacy.
Funding
$208M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Patients with relapsed or refractory cancers, including solid tumors and hematologic malignancies, often face limited effective treatment options. Traditional cancer therapies may fail to provide lasting remission, and the availability of suitable autologous cell therapies can be restricted by prior treatments or disease progression.
Solution
Wugen is developing off-the-shelf allogeneic cellular therapies, including CAR-T and NK cell treatments, designed to provide readily available and effective treatment options for patients with cancers. These therapies utilize engineered cells derived from healthy donors, offering a consistent and scalable source of therapeutic cells. By leveraging allogeneic cells, Wugen aims to overcome the limitations associated with autologous approaches and enhance therapeutic efficacy against solid tumors and hematologic malignancies. The company's pipeline includes both CAR-T and NK cell therapies, each engineered to target specific cancer antigens and elicit a potent anti-tumor response.
Target Audience
The primary target audience includes patients with relapsed or refractory hematologic malignancies and solid tumors who have exhausted other treatment options, as well as the physicians who treat them.
Features
- Allogeneic CAR-T cell therapy (WU-CART) targeting T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL)
- Allogeneic memory NK cell therapy (WU-NK-101) for acute myeloid leukemia (AML)
- Engineered NK cell therapy (WU-NK-201) for solid tumors
- Enhanced cytotoxicity and tumor infiltration capabilities through proprietary engineering approaches
- Off-the-shelf availability, enabling rapid treatment initiation
- Potential for combination with monoclonal antibodies (mAbs) to enhance anti-tumor activity in solid tumors